Rivaroxaban  	Rivaroxaban  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
venous  	venous  	 JJ	B-NP
thromboembolism 	thromboembolism 	 NN	I-NP
:  	:  	 :	O
a  	a  	 DT	O
single  	single  	 JJ	O
technology  	technology  	 NN	B-NP
appraisal  	appraisal  	 VBD	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
rivaroxaban  	rivaroxaban  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
venous  	venous  	 JJ	B-NP
thromboembolism  	thromboembolism  	 NNS	I-NP
( 	( 	 -LRB-	O
VTE 	VTE 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
adult  	adult  	 NN	O
patients  	patients  	 NNS	O
undergoing  	undergoing  	 VBG	O
elective  	elective  	 JJ	B-NP
hip  	hip  	 NN	I-NP
or  	or  	 CC	O
knee  	knee  	 JJ	O
replacement  	replacement  	 NN	O
surgery  	surgery  	 NN	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
evidence  	evidence  	 NN	O
came  	came  	 VBD	O
from  	from  	 IN	O
four  	four  	 CD	O
randomised  	randomised  	 NNS	B-NP
controlled  	controlled  	 VBN	I-NP
trials  	trials  	 NNS	I-NP
( 	( 	 -LRB-	O
RCTs 	RCTs 	 NNP	B-NP
)  	)  	 -RRB-	O
comparing  	comparing  	 VBG	B-NP
rivaroxaban  	rivaroxaban  	 NN	I-NP
with  	with  	 IN	O
enoxaparin  	enoxaparin  	 NNS	B-NP
[ 	[ 	 -LRB-	O
RECORD  	RECORD  	 NNP	O
( 	( 	 -LRB-	O
Regulation  	Regulation  	 NNP	O
of  	of  	 IN	O
Coagulation  	Coagulation  	 NNP	B-NP
in  	in  	 IN	O
Orthopedic  	Orthopedic  	 NNP	B-NP
surgery  	surgery  	 NN	I-NP
to  	to  	 TO	O
pRevent  	pRevent  	 JJ	O
Deep  	Deep  	 JJ	O
venous  	venous  	 JJ	O
thrombosis  	thrombosis  	 NN	O
and  	and  	 CC	O
pulmonary  	pulmonary  	 JJ	B-NP
embolism 	embolism 	 NN	I-NP
)  	)  	 -RRB-	O
1-4 	1-4 	 CD	O
]  	]  	 -RRB-	O
and  	and  	 CC	O
three  	three  	 CD	O
comparing  	comparing  	 JJ	O
dabigatran  	dabigatran  	 NN	B-NP
with  	with  	 IN	O
enoxaparin  	enoxaparin  	 NNS	B-NP
[ 	[ 	 -LRB-	O
RE-NOVATE  	RE-NOVATE  	 NNP	B-NP
( 	( 	 -LRB-	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
venous  	venous  	 JJ	B-NP
thromboembolism  	thromboembolism  	 NN	I-NP
after  	after  	 IN	O
total  	total  	 JJ	B-NP
hip  	hip  	 JJ	I-NP
replacement  	replacement  	 NN	I-NP
trial 	trial 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
RE-MODEL  	RE-MODEL  	 NNP	B-NP
( 	( 	 -LRB-	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
venous  	venous  	 JJ	B-NP
thromboembolism  	thromboembolism  	 NN	I-NP
after  	after  	 IN	O
total  	total  	 JJ	B-NP
knee  	knee  	 NN	I-NP
replacement  	replacement  	 NN	I-NP
trial 	trial 	 NN	I-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
RE-MOBILIZE  	RE-MOBILIZE  	 NNP	O
( 	( 	 -LRB-	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
venous  	venous  	 JJ	B-NP
thromboembolism  	thromboembolism  	 NN	I-NP
after  	after  	 IN	O
total  	total  	 JJ	B-NP
knee  	knee  	 NN	I-NP
arthroplasty  	arthroplasty  	 NN	I-NP
trial 	trial 	 NN	I-NP
) 	) 	 -RRB-	O
] 	] 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
evidence  	evidence  	 NN	O
from  	from  	 IN	O
the  	the  	 DT	O
four  	four  	 CD	O
RECORD  	RECORD  	 NN	B-NP
trials  	trials  	 NNS	I-NP
indicates  	indicates  	 VBZ	O
that  	that  	 DT	O
rivaroxaban  	rivaroxaban  	 NN	B-NP
had  	had  	 VBD	O
superior  	superior  	 JJ	O
efficacy  	efficacy  	 NN	O
over  	over  	 IN	O
enoxaparin  	enoxaparin  	 NN	B-NP
after  	after  	 IN	O
total  	total  	 JJ	B-NP
hip  	hip  	 JJ	I-NP
replacement  	replacement  	 NN	I-NP
( 	( 	 -LRB-	O
THR 	THR 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
total  	total  	 JJ	B-NP
knee  	knee  	 NN	I-NP
replacement  	replacement  	 NN	I-NP
( 	( 	 -LRB-	O
TKR 	TKR 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
composite  	composite  	 JJ	O
primary  	primary  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
of  	of  	 IN	O
any  	any  	 DT	O
deep  	deep  	 JJ	B-NP
vein  	vein  	 NN	I-NP
thrombosis  	thrombosis  	 NNS	I-NP
( 	( 	 -LRB-	O
DVT 	DVT 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
non-fatal  	non-fatal  	 FW	B-NP
pulmonary  	pulmonary  	 FW	I-NP
embolism  	embolism  	 FW	I-NP
( 	( 	 -LRB-	O
PE 	PE 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
death  	death  	 NN	O
from  	from  	 IN	O
all  	all  	 DT	O
causes  	causes  	 VBZ	O
the  	the  	 DT	O
relative  	relative  	 JJ	B-NP
risk  	risk  	 NN	I-NP
reductions  	reductions  	 NNS	I-NP
were  	were  	 VBD	O
70-79 	70-79 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
THR  	THR  	 NNP	B-NP
and  	and  	 CC	O
31-49 	31-49 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
TKR 	TKR 	 NNP	B-NP
.  	.  	 .	O
Rivaroxaban  	Rivaroxaban  	 NNP	B-NP
also  	also  	 RB	O
had  	had  	 VBD	O
superior  	superior  	 JJ	O
efficacy  	efficacy  	 NN	O
over  	over  	 IN	O
enoxaparin  	enoxaparin  	 NN	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
secondary  	secondary  	 JJ	I-NP
outcome  	outcome  	 NN	I-NP
major  	major  	 JJ	O
VTE 	VTE 	 NNP	B-NP
.  	.  	 .	O
Rivaroxaban  	Rivaroxaban  	 NNP	B-NP
was  	was  	 VBD	O
not  	not  	 RB	O
inferior  	inferior  	 JJ	O
to  	to  	 TO	O
enoxaparin  	enoxaparin  	 VB	O
on  	on  	 IN	O
the  	the  	 DT	O
safety  	safety  	 NN	O
outcome  	outcome  	 NN	O
of  	of  	 IN	O
major  	major  	 JJ	O
bleeding 	bleeding 	 NN	O
.  	.  	 .	O
After  	After  	 IN	O
the  	the  	 DT	O
correction  	correction  	 NN	O
of  	of  	 IN	O
some  	some  	 DT	O
errors  	errors  	 NNS	O
found  	found  	 VBD	O
by  	by  	 IN	O
the  	the  	 DT	O
ERG 	ERG 	 NNP	O
,  	,  	 ,	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
economic  	economic  	 JJ	B-NP
model  	model  	 NN	I-NP
represented  	represented  	 VBD	O
a  	a  	 DT	O
reasonable  	reasonable  	 JJ	O
model  	model  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	B-NP
prophylaxis  	prophylaxis  	 NN	I-NP
for  	for  	 IN	I-NP
THR  	THR  	 NNP	I-NP
or  	or  	 CC	O
TKR 	TKR 	 NNP	B-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
base-case  	base-case  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
rivaroxaban  	rivaroxaban  	 VBP	O
dominated  	dominated  	 VBN	O
both  	both  	 DT	O
enoxaparin  	enoxaparin  	 NN	B-NP
and  	and  	 CC	O
dabigatran 	dabigatran 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
incremental  	incremental  	 JJ	B-NP
costs  	costs  	 NNS	I-NP
saved  	saved  	 VBN	O
and  	and  	 CC	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-years  	life-years  	 NN	I-NP
( 	( 	 -LRB-	O
QALYs 	QALYs 	 NNP	B-NP
)  	)  	 -RRB-	O
gained  	gained  	 VBD	O
were  	were  	 VBD	O
small  	small  	 JJ	O
( 	( 	 -LRB-	O
below  	below  	 IN	O
200  	200  	 CD	O
pounds  	pounds  	 NNS	O
and  	and  	 CC	O
0.005 	0.005 	 NNP	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
,  	,  	 ,	O
per  	per  	 IN	O
person 	person 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Analyses  	Analyses  	 NNP	O
were  	were  	 VBD	O
conducted  	conducted  	 VBN	O
sampling  	sampling  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
distributions  	distributions  	 NNS	B-NP
observed  	observed  	 VBD	O
from  	from  	 IN	O
the  	the  	 DT	O
RCTs 	RCTs 	 JJ	O
.  	.  	 .	O
When  	When  	 WRB	O
all  	all  	 DT	O
parameters  	parameters  	 NN	O
were  	were  	 VBD	O
sampled  	sampled  	 VBN	B-NP
rivaroxaban  	rivaroxaban  	 NNS	I-NP
dominated  	dominated  	 VBD	O
enoxaparin  	enoxaparin  	 VBN	O
in  	in  	 IN	O
all  	all  	 DT	O
scenarios  	scenarios  	 NNS	O
except  	except  	 IN	O
for  	for  	 IN	O
two 	two 	 CD	O
,  	,  	 ,	O
in  	in  	 IN	O
which  	which  	 WDT	O
enoxaparin  	enoxaparin  	 VBZ	O
produced  	produced  	 VBN	O
more  	more  	 RBR	O
QALYs  	QALYs  	 JJ	O
than  	than  	 IN	O
rivaroxaban  	rivaroxaban  	 NN	B-NP
and  	and  	 CC	O
had  	had  	 VBD	O
an  	an  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost  	cost  	 NN	I-NP
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
gained  	gained  	 VBD	O
of  	of  	 IN	O
5000  	5000  	 CD	O
pounds  	pounds  	 NNS	O
and  	and  	 CC	O
8000  	8000  	 CD	O
pounds  	pounds  	 NNS	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
Rivaroxaban  	Rivaroxaban  	 NNP	B-NP
dominated  	dominated  	 VBD	O
dabigatran  	dabigatran  	 VBN	O
when  	when  	 WRB	O
RECORD  	RECORD  	 NNP	O
1  	1  	 CD	O
and  	and  	 CC	O
RECORD  	RECORD  	 NNP	O
2 	2 	 CD	O
,  	,  	 ,	O
individually  	individually  	 RB	O
or  	or  	 CC	O
pooled 	pooled 	 NN	O
,  	,  	 ,	O
were  	were  	 VBD	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
RE-NOVATE  	RE-NOVATE  	 JJ	B-NP
and  	and  	 CC	O
when  	when  	 WRB	O
all  	all  	 DT	O
four  	four  	 CD	O
rivaroxaban  	rivaroxaban  	 CD	B-NP
RCTs  	RCTs  	 JJ	I-NP
pooled  	pooled  	 NN	I-NP
were  	were  	 VBD	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
all  	all  	 DT	O
three  	three  	 CD	O
dabigatran  	dabigatran  	 JJ	B-NP
RCTs 	RCTs 	 NN	I-NP
.  	.  	 .	O
Dabigatran  	Dabigatran  	 FW	B-NP
dominated  	dominated  	 FW	I-NP
rivaroxaban  	rivaroxaban  	 FW	I-NP
comparing  	comparing  	 FW	O
RECORD  	RECORD  	 NNP	O
4  	4  	 CD	O
with  	with  	 IN	O
RE-MODEL  	RE-MODEL  	 JJ	B-NP
and  	and  	 CC	O
RE-MOBILIZE 	RE-MOBILIZE 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
was  	was  	 VBD	O
more  	more  	 RBR	O
cost-effective  	cost-effective  	 JJ	O
than  	than  	 IN	O
rivaroxaban  	rivaroxaban  	 NNS	B-NP
comparing  	comparing  	 VBG	I-NP
RECORD  	RECORD  	 NNP	I-NP
3  	3  	 CD	O
( 	( 	 -LRB-	O
incremental  	incremental  	 JJ	B-NP
cost  	cost  	 NN	I-NP
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
gained  	gained  	 VBD	O
of  	of  	 IN	O
rivaroxaban  	rivaroxaban  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
dabigatran  	dabigatran  	 NN	B-NP
of  	of  	 IN	O
123,000  	123,000  	 CD	O
pounds 	pounds 	 NNS	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
RECORD  	RECORD  	 NNP	O
3  	3  	 CD	O
and  	and  	 CC	O
RECORD  	RECORD  	 NNP	O
4  	4  	 CD	O
pooled  	pooled  	 NNS	O
( 	( 	 -LRB-	O
incremental  	incremental  	 JJ	B-NP
cost  	cost  	 NN	I-NP
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
gained  	gained  	 VBD	O
of  	of  	 IN	O
dabigatran  	dabigatran  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
rivaroxaban  	rivaroxaban  	 NN	B-NP
of  	of  	 IN	O
400  	400  	 CD	O
pounds 	pounds 	 NNS	O
)  	)  	 -RRB-	O
with  	with  	 IN	O
RE-MODEL  	RE-MODEL  	 JJ	B-NP
and  	and  	 CC	O
RE-MOBILIZE 	RE-MOBILIZE 	 JJ	O
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
evidence  	evidence  	 NN	O
indicates  	indicates  	 VBZ	O
that  	that  	 DT	O
rivaroxaban  	rivaroxaban  	 NN	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
inferior  	inferior  	 JJ	O
to  	to  	 TO	O
enoxaparin  	enoxaparin  	 VB	O
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	O
and  	and  	 CC	O
secondary  	secondary  	 JJ	B-NP
outcomes 	outcomes 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
submission  	submission  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
reasonable  	reasonable  	 JJ	O
estimation  	estimation  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	O
rivaroxaban  	rivaroxaban  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
enoxaparin  	enoxaparin  	 NN	B-NP
and  	and  	 CC	O
dabigatran 	dabigatran 	 NN	B-NP
,  	,  	 ,	O
although  	although  	 IN	O
the  	the  	 DT	O
uncertainty  	uncertainty  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
decision  	decision  	 NN	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
underestimated 	underestimated 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
are  	are  	 VBP	O
particularly  	particularly  	 RB	O
sensitive  	sensitive  	 JJ	O
to  	to  	 TO	O
any  	any  	 DT	O
assumed  	assumed  	 JJ	O
difference  	difference  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
fatal  	fatal  	 JJ	B-NP
PEs 	PEs 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
the  	the  	 DT	O
ERG  	ERG  	 NNP	O
does  	does  	 VBZ	O
not  	not  	 RB	O
believe  	believe  	 VBP	O
there  	there  	 EX	O
is  	is  	 VBZ	O
sufficient  	sufficient  	 JJ	O
evidence  	evidence  	 NN	O
to  	to  	 TO	O
support  	support  	 VB	O
a  	a  	 DT	O
difference  	difference  	 NN	O
between  	between  	 IN	O
interventions 	interventions 	 NNS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
NICE  	NICE  	 NNP	O
guidance  	guidance  	 VBD	O
issued  	issued  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
STA  	STA  	 NNP	B-NP
states  	states  	 NNS	I-NP
that 	that 	 IN	O
:  	:  	 :	O
riveroxaban 	riveroxaban 	 CD	B-NP
,  	,  	 ,	O
within  	within  	 IN	O
its  	its  	 PRP$	O
marketing  	marketing  	 NN	B-NP
authorisation 	authorisation 	 NN	I-NP
,  	,  	 ,	O
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
as  	as  	 IN	O
an  	an  	 DT	O
option  	option  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
venous  	venous  	 JJ	B-NP
thromboembolism  	thromboembolism  	 NN	I-NP
in  	in  	 IN	O
adults  	adults  	 NNS	O
having  	having  	 VBG	O
elective  	elective  	 JJ	B-NP
THR  	THR  	 NNP	I-NP
or  	or  	 CC	O
elective  	elective  	 JJ	B-NP
TKB 	TKB 	 NNP	I-NP
.  	.  	 .	O
